The estimated Net Worth of Elizabeth A. Barrett is at least $30.4 Million dollars as of 31 January 2023. Ms. Barrett owns over 18,333 units of UroGen Pharma Ltd stock worth over $4,511,603 and over the last 6 years she sold URGN stock worth over $0. In addition, she makes $25,900,800 as President, Chief Executive Officer, and Director at UroGen Pharma Ltd.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Ms. Barrett URGN stock SEC Form 4 insiders trading
Elizabeth has made over 11 trades of the UroGen Pharma Ltd stock since 2019, according to the Form 4 filled with the SEC. Most recently she exercised 18,333 units of URGN stock worth $253,179 on 31 January 2023.
The largest trade she's ever made was exercising 105,689 units of UroGen Pharma Ltd stock on 3 January 2022 worth over $1,459,565. On average, Elizabeth trades about 20,278 units every 62 days since 2019. As of 31 January 2023 she still owns at least 326,691 units of UroGen Pharma Ltd stock.
You can see the complete history of Ms. Barrett stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Elizabeth Barrett biography
Elizabeth Barrett is President, Chief Executive Officer, Director of the Company. Before joining us Ms. Barrett served as the Chief Executive Officer of Novartis Oncology and as a member of the Executive Committee of Novartis since February 2018. Prior to that, Ms. Barrett served at Pfizer Inc. in various capacities, most recently as the Global President of Oncology, and before that as Pfizer’s Regional President of US Oncology Business Unit since March 2009. Prior to Pfizer, she was Vice President and General Manager of the Oncology Business Unit at Cephalon Inc. Ms. Barrett received a Bachelor of Science in Business Administration from the University of Louisiana in Lafayette, Louisiana and a Master’s in Business Administration-Marketing from St. Joseph’s University in Philadelphia, Pennsylvania. Our Board believes Ms. Barrett’s leadership of both large organizations and growing businesses qualifies her to serve on our board of directors.
What is the salary of Elizabeth Barrett?
As the President, Chief Executive Officer, and Director of UroGen Pharma Ltd, the total compensation of Elizabeth Barrett at UroGen Pharma Ltd is $25,900,800. There are no executives at UroGen Pharma Ltd getting paid more.
How old is Elizabeth Barrett?
Elizabeth Barrett is 57, she's been the President, Chief Executive Officer, and Director of UroGen Pharma Ltd since 2019. There are 8 older and 7 younger executives at UroGen Pharma Ltd. The oldest executive at UroGen Pharma Ltd is Stuart Holden, 77, who is the Independent Director.
What's Elizabeth Barrett's mailing address?
Elizabeth's mailing address filed with the SEC is 210 EAST GRAND AVENUE, , SOUTH SAN FRANCISCO, CA, 94080.
Insiders trading at UroGen Pharma Ltd
Over the last 7 years, insiders at UroGen Pharma Ltd have traded over $8,740,363 worth of UroGen Pharma Ltd stock and bought 33,940 units worth $791,524 . The most active insiders traders include Ran Nussbaum, Arie Belldegrun, and Kathryn E Falberg. On average, UroGen Pharma Ltd executives and independent directors trade stock every 31 days with the average trade being worth of $214,027. The most recent stock trade was executed by Mark Schoenberg on 10 June 2024, trading 10,000 units of URGN stock currently worth $138,100.
What does UroGen Pharma Ltd do?
urogen pharma ltd. (nasdaq:urgn) is a clinical-stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology. the company has developed rtgel™, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. urogen pharma's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. urogen pharma's lead product candidates, mitogel™ (mitomycin urothelial gel) and vesigel™ (mitomycin intravesical gel), are designed to potentially remove tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma and bladder cancer, respectively. urogen pharma is headquartered in ra’anana, israel with u.s. headquarters in new york.
What does UroGen Pharma Ltd's logo look like?
Complete history of Ms. Barrett stock trades at UroGen Pharma Ltd and Allogene Therapeutics Inc
UroGen Pharma Ltd executives and stock owners
UroGen Pharma Ltd executives and other stock owners filed with the SEC include:
-
Elizabeth Barrett,
President, Chief Executive Officer, Director -
Elizabeth A. Barrett,
Pres, CEO & Director -
Mark Schoenberg,
Chief Medical Officer -
Ron Bentsur,
Advisor -
Dr. Mark P. Schoenberg,
Chief Medical Officer -
Arie Belldegrun,
Independent Chairman of the Board -
Jason Drew Smith,
Gen. Counsel & Chief Compliance Officer -
Cynthia Butitta,
Independent Director -
Kathryn Falberg,
Independent Director -
Stuart Holden,
Independent Director -
Ran Nussbaum,
Independent Director -
Fred Cohen,
Independent Director -
Shawn Tomasello,
Independent Director -
Molly Henderson CPA, MBA,
Chief Financial Officer -
Elyse Seltzer,
Chief Development Officer -
Polly Murphy,
Chief Business Officer -
Jeff Bova,
Chief Commercial Officer -
Jason Smith,
Chief Compliance Officer, General Counsel -
Jim Ottinger,
Executive Vice President, Regulatory Affairs and Quality -
Marina Konorty,
Executive Vice President, Research & Development and Technical Operations -
Molly Henderson,
Chief Financial Officer, Principal Accounting Officer -
James Ottinger R.ph.,
Exec. VP of Regulatory Affairs & Quality -
Jeffrey Bova M.B.A.,
Chief Commercial Officer -
Dr. Sari Prutchi-Sagiv Ph.D.,
Marketing Director -
Eric Van Zanten,
Sr. Director of Communications -
Jason Smith,
Gen. Counsel & Chief Compliance Officer -
Sara Blum Sherman,
Sr. Director of Investor Relations -
James A. Jr. Robinson,
Director -
Investments Iv, L.P.Pro Que...,
-
Stephen Mullennix,
Chief Operating Officer -
Peter P. Pfreundschuh,
Chief Financial Officer -
Leana Wen,
Director -
Dong Kim,
Chief Financial Officer -
Daniel George Wildman,
Director